

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – February 28, 2007

**NOTICE OF STATUS CHANGE**

**Study 2** will re-open for 3 additional EIAC patients only at step-down dose level 3ER (OSI-774 at 500 mg) effective Wednesday, February 28, 2007.

**Please retain this notice with the protocol.**